Licence deal
Transgene SA agreed a licence with Australian biotech Virax Holdings Ltd, getting exclusive access to Virax’s Co-X-Gene technology patents for use in two of Transgene’s immunotherapeutic products, TG4010 and TG4001.
TG4010 is currently in phase IIb clinical trials for treating non-small cell lung cancer, while TG4001 is in preparation for phase III trials in treating human papilloma virus infections.
Virax will receive an upfront licence fee and will share in fees and milestone payments received by Transgene if it licenses out either of the products.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
